Viewing Study NCT01261767


Ignite Creation Date: 2025-12-25 @ 12:44 AM
Ignite Modification Date: 2026-03-11 @ 2:53 PM
Study NCT ID: NCT01261767
Status: TERMINATED
Last Update Posted: 2017-02-09
First Post: 2010-12-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
Sponsor: Novo Nordisk A/S
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module